Understanding and treating developmental brain disorders

Neurochlore no longer carries out experimental (animal) research on autism following the failure of phase 3: our fundamental research was stopped, the researchers, engineers and technicians had to leave the company and the equipment sold.

However, Neurochlore invests in B&A Oncomedical and B&A Biomedical on the treatment of cancers and the prediction by Machine Learning, in humans, of neurological and psychiatric diseases.


Past research

Our research aims at determining brain development alterations that lead to Autism Spectrum Disorders (ASD) and other Neurodevelopmental Disorders and identifying therapeutic targets.